Impact Partnership Wealth LLC Purchases Shares of 18,323 Royalty Pharma plc (NASDAQ:RPRX)

Impact Partnership Wealth LLC bought a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,323 shares of the biopharmaceutical company's stock, valued at approximately $467,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Ballentine Partners LLC purchased a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $200,000. Brooklyn Investment Group raised its stake in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 876 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $486,000. Pallas Capital Advisors LLC purchased a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $2,355,000. Finally, Ridgewood Investments LLC raised its stake in shares of Royalty Pharma by 40.8% during the fourth quarter. Ridgewood Investments LLC now owns 30,735 shares of the biopharmaceutical company's stock worth $784,000 after purchasing an additional 8,913 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Up 1.4 %

NASDAQ:RPRX traded up $0.44 on Friday, reaching $31.06. The stock had a trading volume of 5,780,069 shares, compared to its average volume of 4,150,138. The company has a 50-day moving average of $26.67 and a 200 day moving average of $27.31. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market cap of $18.30 billion, a P/E ratio of 16.09 and a beta of 0.47. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $31.66.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.83%. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma's dividend payout ratio (DPR) is 43.52%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of recent analyst reports. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup dropped their price objective on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, October 25th. Finally, StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.